JP2025087691A5 - - Google Patents
Info
- Publication number
- JP2025087691A5 JP2025087691A5 JP2025017262A JP2025017262A JP2025087691A5 JP 2025087691 A5 JP2025087691 A5 JP 2025087691A5 JP 2025017262 A JP2025017262 A JP 2025017262A JP 2025017262 A JP2025017262 A JP 2025017262A JP 2025087691 A5 JP2025087691 A5 JP 2025087691A5
- Authority
- JP
- Japan
- Prior art keywords
- tada
- amino acid
- adenosine deaminase
- gsd1a
- base editor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805271P | 2019-02-13 | 2019-02-13 | |
| US62/805,271 | 2019-02-13 | ||
| US201962852228P | 2019-05-23 | 2019-05-23 | |
| US201962852224P | 2019-05-23 | 2019-05-23 | |
| US62/852,224 | 2019-05-23 | ||
| US62/852,228 | 2019-05-23 | ||
| US201962876354P | 2019-07-19 | 2019-07-19 | |
| US62/876,354 | 2019-07-19 | ||
| US201962912992P | 2019-10-09 | 2019-10-09 | |
| US62/912,992 | 2019-10-09 | ||
| US201962931722P | 2019-11-06 | 2019-11-06 | |
| US62/931,722 | 2019-11-06 | ||
| US201962941569P | 2019-11-27 | 2019-11-27 | |
| US62/941,569 | 2019-11-27 | ||
| US202062966526P | 2020-01-27 | 2020-01-27 | |
| US62/966,526 | 2020-01-27 | ||
| PCT/US2020/018124 WO2020168088A1 (en) | 2019-02-13 | 2020-02-13 | Compositions and methods for treating glycogen storage disease type 1a |
| JP2021546892A JP7631209B2 (ja) | 2019-02-13 | 2020-02-13 | 糖原病１ａ型を治療するための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546892A Division JP7631209B2 (ja) | 2019-02-13 | 2020-02-13 | 糖原病１ａ型を治療するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025087691A JP2025087691A (ja) | 2025-06-10 |
| JP2025087691A5 true JP2025087691A5 (https=) | 2025-11-26 |
Family
ID=72045644
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546892A Active JP7631209B2 (ja) | 2019-02-13 | 2020-02-13 | 糖原病１ａ型を治療するための組成物および方法 |
| JP2025017262A Pending JP2025087691A (ja) | 2019-02-13 | 2025-02-05 | 糖原病１ａ型を治療するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546892A Active JP7631209B2 (ja) | 2019-02-13 | 2020-02-13 | 糖原病１ａ型を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220127594A1 (https=) |
| EP (1) | EP3924478A4 (https=) |
| JP (2) | JP7631209B2 (https=) |
| KR (1) | KR20210129108A (https=) |
| CN (2) | CN120138047A (https=) |
| AU (1) | AU2020221355A1 (https=) |
| CA (1) | CA3128886A1 (https=) |
| WO (1) | WO2020168088A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178427A1 (en) | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| WO2019222555A1 (en) | 2018-05-16 | 2019-11-21 | Arbor Biotechnologies, Inc. | Novel crispr-associated systems and components |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| AU2020215730A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| WO2020168088A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| JP2023505234A (ja) * | 2019-12-04 | 2023-02-08 | アーバー バイオテクノロジーズ， インコーポレイテッド | ヌクレアーゼを含む組成物及びその使用 |
| US12416001B2 (en) * | 2020-02-14 | 2025-09-16 | Ohio State Innovation Foundation | Nucleobase editors and methods of use thereof |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| CA3198671A1 (en) * | 2020-10-14 | 2022-04-21 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| EP4504947A4 (en) * | 2022-04-07 | 2026-03-25 | Univ Duke | COMPOSITIONS AND METHODS TO PROMOTE LIVER REGENERATION BY GENE EDITING IN METABOLIC LIVER DISEASE |
| CN117568313B (zh) * | 2024-01-15 | 2024-04-26 | 上海贝斯昂科生物科技有限公司 | 基因编辑组合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL310721B2 (en) * | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| BR112018008971A2 (pt) * | 2015-11-06 | 2018-11-27 | Crispr Therapeutics Ag | materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a |
| LT3436077T (lt) * | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2018020323A2 (en) * | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
| CN110214183A (zh) * | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| RU2019130504A (ru) * | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| KR102761791B1 (ko) * | 2017-06-26 | 2025-02-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법 |
| US10392616B2 (en) * | 2017-06-30 | 2019-08-27 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
| CN111801345A (zh) * | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| KR20250133482A (ko) * | 2018-05-11 | 2025-09-05 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법 |
| WO2020168088A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| EP4100519A2 (en) * | 2020-02-05 | 2022-12-14 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
-
2020
- 2020-02-13 WO PCT/US2020/018124 patent/WO2020168088A1/en not_active Ceased
- 2020-02-13 CA CA3128886A patent/CA3128886A1/en active Pending
- 2020-02-13 CN CN202510269938.1A patent/CN120138047A/zh active Pending
- 2020-02-13 KR KR1020217029280A patent/KR20210129108A/ko active Pending
- 2020-02-13 US US17/430,274 patent/US20220127594A1/en active Pending
- 2020-02-13 EP EP20754972.6A patent/EP3924478A4/en active Pending
- 2020-02-13 AU AU2020221355A patent/AU2020221355A1/en active Pending
- 2020-02-13 JP JP2021546892A patent/JP7631209B2/ja active Active
- 2020-02-13 CN CN202080028267.5A patent/CN114026237B/zh active Active
-
2025
- 2025-02-05 JP JP2025017262A patent/JP2025087691A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025087691A5 (https=) | ||
| JP2022519882A5 (https=) | ||
| JP2025037975A5 (https=) | ||
| JP2024038327A5 (https=) | ||
| Van Ormondt et al. | Nucleotide sequences of adenovirus DNAs | |
| JP2022519761A5 (https=) | ||
| CN102942618B (zh) | 具有肿瘤细胞杀伤活性的端粒蛋白多肽片段及其应用 | |
| JP2025102768A5 (https=) | ||
| JP2021521855A5 (https=) | ||
| JP2023545497A5 (https=) | ||
| JP2021536250A5 (https=) | ||
| US12304933B2 (en) | Disease treatment drug based on mesenchymal-stem-cell mobilization | |
| CN117568313B (zh) | 基因编辑组合物及其用途 | |
| JP2004501650A5 (https=) | ||
| Wu et al. | Pre-and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha | |
| US20250288691A1 (en) | Compositions and methods for epigenetic regulation of hbv gene expression | |
| JP6903633B2 (ja) | 腫瘍抑制ペプチド | |
| CN114438106B (zh) | Rv2779c基因及其表达产物作为抗结核分枝杆菌靶点的应用 | |
| SONG et al. | Conservation of DNA sequence in the predicted major late promoter regions of selected mastadenoviruses | |
| Schöndorf et al. | Characterization of the complete genome of the Tupaia (tree shrew) adenovirus | |
| CN118649229B (zh) | 工程化Cas9蛋白及其制备方法和应用 | |
| JP2018536428A5 (https=) | ||
| CN106244556B (zh) | 定点突变ApoE基因的方法 | |
| Vrati et al. | Nucleotide sequence of ovine adenovirus tripartite leader sequence and homologues of the IVa2, DNA polymerase and terminal proteins | |
| US20050271622A1 (en) | Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof |